title: The functional effect of epigallocatechin gallate on ischemic stroke in rats.
abstract: We evaluated the efficacy of epigallocatechin gallate (EGCG) for improving function in rats with transient middle cerebral artery occlusion (MCAO). Three procedures underwent for each groups; MCAO and EGCG treatment, MCAO without treatment (MCAO control), and sham operation. Function was evaluated on days 1, 5, 10, and 14 after ischemia, using a modified sticky-tape test and the percentage weight borne on the paretic leg. Infarct volume did not differ between the EGCG-treated and MCAO control groups. Compared with the MCAO control group, the EGCG-treated group showed improved forelimb function and had normal function by day 10 (P<0.05). The improvements persisted until day 14 postischemia. In contrast, hind limb function did not differ between the EGCG-treated and MCAO control groups. Thus, EGCG improved certain aspects of function of forelimb until day 14 after MCAO in rats.
authors.affiliation: Department of Rehabilitation Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Seong Hoon
authors.initials: SH
authors.lastname: Lim
authors.forename: Han Seung
authors.initials: HS
authors.lastname: Kim
authors.forename: Young Kook
authors.initials: YK
authors.lastname: Kim
authors.forename: Tae Min
authors.initials: TM
authors.lastname: Kim
authors.forename: Sun
authors.initials: S
authors.lastname: Im
authors.forename: Myung Eun
authors.initials: ME
authors.lastname: Chung
authors.forename: Bo Young
authors.initials: BY
authors.lastname: Hong
authors.forename: Young Jin
authors.initials: YJ
authors.lastname: Ko
authors.forename: Hye Won
authors.initials: HW
authors.lastname: Kim
authors.forename: Jong In
authors.initials: JI
authors.lastname: Lee
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D020520:Brain Infarction / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D002392:Catechin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004195:Disease Models, Animal; D006614:Hindlimb / Q000503:physiopathology; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D055139:Sensory Gating / Q000187:drug effects; D018709:Statistics, Nonparametric
chemical_list: D018696:Neuroprotective Agents; D002392:Catechin; C045651:epigallocatechin gallate